Sales of Humira could peak above $18 billion – CEO
California’s Kite strikes deals with Fosun and Daiichi Sankyo.
Pharma M&A could surge in 2017, says report
FDA concerned over potential liver toxicity.
Blockbuster likely to face cheap near-copy for first time.
AbbVie blood cancer drug tipped to be a blockbuster.
Biotech plans pivotal trial next year.
Kite to start filing data for KTE-C19 with US regulator.